Abstract
Beta-2-microglobulin (β-2M) was determined in serum, urine and dialysate using immunochemiluminesce (Immulite DPC, La Garenne Colombes, France) and immunoturbidimetric assay (Olympus, Rungis, France) and was compared with radio-immunoassay (Immunotech, Marseille, France). One hundred and eighty-nine patients suffering from myeloma ( N =66), end stage renal failure ( N =54) or inflammation ( N =69) were included in this study. On serum, immunochemiluminescence and immunoturbidimetric assays have reliable analytical performances. Values obtained with clinical samples are highly correlated to radio-immunoassay (DPC–RIA r 2=0.84; Olympus–RIA r 2=0.94) whatever the type of pathology. Values obtained with urinary samples ( N =96) are closely related to those obtained with RIA (DPC–RIA r 2 = 0.98; Olympus–RIA: r 2=0.99). Despite the low levels observed in dialysate ( N =57) good correlations between methods (DPC–RIA: r 2=0.47; Olympus–RIA: r 2=0.54 ; Olympus/DPC ; r 2=0.85) are obtained. In conclusion, immunochemiluminescence or immunoturbidimetric assays could be used in routine chemistry in order to determine β2M in plasma, urine and dialysate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
